325 related articles for article (PubMed ID: 34799081)
21. PARP Inhibitors in Prostate Cancer.
Grewal K; Grewal K; Tabbara IA
Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
[TBL] [Abstract][Full Text] [Related]
22. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
[TBL] [Abstract][Full Text] [Related]
23. [PARP inhibitors in first-line of ovarian cancers].
Rodrigues M
Bull Cancer; 2020 Jan; 107(1):4-5. PubMed ID: 31928735
[No Abstract] [Full Text] [Related]
24. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
[TBL] [Abstract][Full Text] [Related]
25. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
26. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
[TBL] [Abstract][Full Text] [Related]
27. PARP inhibitors for ovarian cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
[No Abstract] [Full Text] [Related]
28. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
Genestie C; Gladieff L; Frère-Belda ML; Lortholary A; Vaur D; Treilleux I; Lyonnet DS
Bull Cancer; 2021 Dec; 108(9S1):S33-S38. PubMed ID: 34955160
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
[TBL] [Abstract][Full Text] [Related]
31. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
32. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
33. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
[TBL] [Abstract][Full Text] [Related]
34. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
[TBL] [Abstract][Full Text] [Related]
35. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
38. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
39. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
40. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]